Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 19/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.55 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.55 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.55 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.55 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.55 |
| ▸ | ATR | Q13535 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12264107 | 0.94 | MTOR (0.59) | MTORPIK3CAPIK3CGRICTORRPTOR | |
| SCHEMBL1497727 | 0.90 | MTOR (0.59) | MTORPIK3CAPIK3CGRICTORRPTOR | |
| SCHEMBL1497733 | 0.88 | MTOR (0.73) | MTORPIK3CAPIK3CGATR | |
| SCHEMBL12832137 | 0.82 | PIK3CA (0.73) | MTORPIK3CA | |
| SCHEMBL4996123 | 0.80 | MTOR (0.67) | MTORPIK3CAPIK3CGRICTORRPTOR | |
| SCHEMBL1497582 | 0.78 | PIK3CA (0.83) | MTORPIK3CAPIK3CGATR | |
| SCHEMBL1497478 | 0.78 | PIK3CA (0.77) | MTORPIK3CAPIK3CGRICTORRPTOR | |
| SCHEMBL12264856 | 0.78 | PIK3CA (0.75) | MTORPIK3CA | |
| SCHEMBL12264851 | 0.78 | PIK3CA (0.76) | MTORPIK3CAPIK3CG | |
| SCHEMBL4992836 | 0.77 | MTOR (0.68) | MTORPIK3CAPIK3CGRICTORRPTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102625708-A | Pi3 kinase inhibitors and uses thereof | AVILA THERAPEUTICS INC | 2012-08-01 | — | — | CN | disclosed |
| EP-2475375-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | MTOR 37/4885PIK3CA 1/4885PIK3CG 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.